HOME >> MEDICINE >> NEWS
Most children with acute sinusitis recover without antibiotics

t of those on the placebo. Side effects such as nausea and diarrhea were more common among the children taking an antibiotic, appearing in 19 percent of those on amoxicillin, 11 percent of those on amoxicillin-clavulanate and 10 percent of the placebo group.

Some patients who improved initially then relapsed after three or four weeks. Other patients symptoms reappeared in the second month after treatment began. However there were no differences among the three groups.

"In a sense, we have met the enemy, and we are it," says Elliot Gellman, M.D., clinical professor of pediatrics. "Many people who come into the office say they are there to get antibiotics for sinus problems."


'"/>

Contact: Anne Enright Shepherd
shepherda@msnotes.wustl.edu
314-286-0119
Washington University School of Medicine
1-Apr-2001


Page: 1 2

Related medicine news :

1. Protecting children from industrial chemicals in the environment
2. Study finds majority of women willing to accept cervical cancer vaccine for self and children
3. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
4. Use of inhaled corticosteroid led to fewer hospitalizations for young children with asthma
5. Pushy parents can be bad for their childrens health
6. Cavity prevention tips for pre-school age children
7. Liverpool to lead 20M Department of Health initiative to develop medicines for children
8. Decreased levels of good cholesterol in children with Progeria may cause premature heart disease
9. Violence exposure and traumatic stress reactions can lead to poor health in children
10. How effective are herbal supplements in reducing illnesses in children?
11. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Most children with acute sinusitis recover without antibiotics

(Date:5/24/2013)... 2013 Gift Card Network members ... in sustainable card material, are combining forces to ... as a sustainable gift card substrate. , The ... challenges and increase education and usage of these ... the reduction of carbon footprint and environmental impact ...
(Date:5/24/2013)... May 24, 2013 Let’s face it: very ... not uncommon for the majority of people to be uncomfortable ... due to a coffee addiction or simply genetics, yellowish or ... are so popular. , Herald Square Dental is ... effective whitening system: Venus White Max. , Teeth become ...
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... to the development of infantile myofibromatosis (IM)a disorder characterized ... tissuemay provide new therapeutic targets, according to researchers from ... findings, published in the American Journal of Human ... this debilitating disease, for which the only current treatment ... IM is an inheritied disorder that develops in infancy ...
(Date:5/24/2013)... Mike Stoler believes that there is much ... in New York. That’s why he hosts “Building ... TV. And that’s why he invited Robert Glazer, ... (ENTA)—the largest single specialty practice in the greater New ... audiology specialists and sub-specialists service communities throughout New York ...
Breaking Medicine News(10 mins):Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Herald Square Dental Introduces New In-office Whitening System: Venus White Max 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4
(Date:5/24/2013)...  An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
(Date:5/23/2013)... 3SBio Inc. (NASDAQ: SSRX ... China -based biotechnology company focused on ... today that, at an extraordinary general meeting held ... favor of the proposal to authorize and approve ... dated February 8, 2013, among Decade Sunshine Limited, ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
Cached News: